News Sentiment

BEAM sentiment intelligence

Beam Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 32.68 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-6.1% over one week, +12.6% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

Understanding the Setup: (BEAM) and Scalable Risk

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -6.1% Price reacting lower
Trend fit Trend active 12.6% over four weeks
Fair value 28.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 36
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
Stock Titan 7
Simply Wall Street 5
TradingView 4
Investing.com 3
simplywall.st 3
Stock Traders Daily 2
Trefis 2

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 12
Regulatory and legal 6
Analyst action 3
Deals and strategy 3
Balance sheet 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 60
Stock Traders Daily Direct company coverage

Understanding the Setup: (BEAM) and Scalable Risk

This article analyzes Beam Therapeutics Inc. (NASDAQ: BEAM), noting weak near and mid-term sentiment despite a positive long-term outlook. It highlights that a breakdown is underway with expected lower levels and elevated downside risk. The analysis provides institutional trading

Tone
Negative 28/100
Event
Guidance
Published
17 Jul 2026 09:41
Source
Stock Traders Daily
Trefis Direct company coverage

Beam Therapeutics Stock 6-Day Losing Spree: Stock Falls 19%

Beam Therapeutics (NASDAQ: BEAM) stock has experienced a significant downturn, falling 19% over a six-day losing streak. This article reports on the stock's recent performance.

Tone
Negative 29/100
Event
Market update
Published
16 Jul 2026 15:40
Source
Trefis
Market source Direct company coverage

Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM)

Bank of America Securities analyst Alec Stranahan reaffirmed a Buy rating for Beam Therapeutics (BEAM) with a $47 target price, citing the limited impact of a recent arbitration resolution on Prime Medicine's PM647. The focus for Beam is now on the execution of its alpha-1 antitr

Tone
Positive 74/100
Event
Analyst action
Published
15 Jul 2026 14:19
Source
Market source
Market source Direct company coverage

Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics

Prime Medicine, Inc. (PRME) announced a positive, binding resolution to its arbitration with Beam Therapeutics regarding their 2019 Collaboration and License Agreement. The Tribunal ruled that Prime Medicine's investigational drug PM647 is within its "Field" as defined by the Agr

Tone
Negative 34/100
Event
Regulatory and legal
Published
15 Jul 2026 09:12
Source
Market source
Stocktwits Direct company coverage

PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug

Prime Medicine (PRME) shares surged 15% after an independent arbitration panel ruled in its favor against Beam Therapeutics (BEAM). The ruling allows Prime to advance its experimental gene-editing drug, PM647, for Alpha-1 Antitrypsin Deficiency, with human trials anticipated in Q

Tone
Neutral 50/100
Event
Market update
Published
12 Jul 2026 04:10
Source
Stocktwits
timothysykes.com Direct company coverage

Beam Therapeutics Inc. (BEAM) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for Beam Therapeutics Inc. (BEAM) stock, showing a current price of $36.02, up $0.20 (0.57%). It also notes that there are no analyst ratings or earnings information currently available for BEAM. The page is hosted by a platform focused o

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 23:10
Source
timothysykes.com
Seeking Alpha Direct company coverage

Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable (PRME)

Prime Medicine (PRME) recently won an arbitration ruling against Beam Therapeutics regarding its PM647 gene editing program for AATD, causing a surge in its stock. While Prime Medicine's platform offers precision, its programs are still preclinical, with clinical data expected in

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 14:44
Source
Seeking Alpha
Simply Wall Street Direct company coverage

Beam Therapeutics (BEAM) On Tribunal Clarity Is It A Buying Opportunity Or Priced In

Beam Therapeutics (BEAM) recently saw its share price rise after a tribunal clarified its collaboration with Prime Medicine, removing monetary risk and clarifying program rights. While narrative analysis suggests the stock is 75% undervalued with a $150 fair value based on its "m

Tone
Positive 70/100
Event
Market update
Published
09 Jul 2026 10:40
Source
Simply Wall Street
GuruFocus Direct company coverage

BEAM Reiterated by B of A Securities -- Price Target Maintained at $47

B of A Securities has reiterated a "Buy" rating for Beam Therapeutics (BEAM), maintaining a price target of $47.00, despite the stock being currently valued as 29.6% overvalued by GuruFocus's GF Value™. The company's GF Score™ is 69/100, showing strong financial stability and mom

Tone
Positive 66/100
Event
Analyst action
Published
08 Jul 2026 23:11
Source
GuruFocus
marketscreener.com Direct company coverage

Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise

Prime Medicine received a favorable ruling in a license arbitration against Beam Therapeutics, leading to a rise in Prime Medicine's shares. This article provides a brief update on this development and lists recent news related to Beam Therapeutics, including its inclusion in var

Tone
Positive 65/100
Event
Market update
Published
08 Jul 2026 18:09
Source
marketscreener.com
grafa.com Direct company coverage

Prime Medicine wins binding arbitration against Beam Therapeutics

Prime Medicine has won a binding legal arbitration dispute against Beam Therapeutics regarding the genetic asset PM647, confirming the development platform falls entirely within Prime Medicine's contractual field. The company will face zero damage penalties and plans to file clin

Tone
Negative 19/100
Event
Market update
Published
08 Jul 2026 16:11
Source
grafa.com
Simply Wall Street Direct company coverage

Russell Value Index Additions Could Be A Game Changer For Beam Therapeutics (BEAM)

Beam Therapeutics (BEAM) was recently added to several Russell Value indices in late June 2026, which is expected to influence trading activity as index-tracking funds adjust their portfolios. While this broad inclusion may impact liquidity and ownership, the company's investment

Tone
Positive 64/100
Event
Balance sheet
Published
07 Jul 2026 07:40
Source
Simply Wall Street
Investing.com Direct company coverage

Beam Therapeutics stock hits 52-week high at 36.89 USD

Beam Therapeutics Inc. (BEAM) stock has surged to a new 52-week high of $36.89, currently trading at $37.02, reflecting a 90.88% increase over the past year. This growth is attributed to investor confidence in its genetic medicine approaches and recent positive developments, incl

Tone
Positive 77/100
Event
Market update
Published
06 Jul 2026 16:39
Source
Investing.com
GuruFocus Direct company coverage

FMR LLC Reduces Stake in Beam Therapeutics Inc.

FMR LLC significantly reduced its stake in Beam Therapeutics Inc. by 86.38%, selling over 10 million shares at $35.24 each. Despite this reduction, Beam Therapeutics still represents 1.65% of FMR LLC's holdings, indicating continued belief in the biotechnology company. Beam Thera

Tone
Negative 39/100
Event
Deals and strategy
Published
04 Jul 2026 00:39
Source
GuruFocus
Stock Titan Direct company coverage

Beam Therapeutics (NASDAQ: BEAM) CMO sells 373 shares for tax withholding

Amy Simon, Chief Medical Officer at Beam Therapeutics Inc. (NASDAQ: BEAM), sold 373 shares of common stock for $34.73 each. This non-discretionary transaction was undertaken to cover tax withholding obligations associated with the vesting of restricted stock units granted under t

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:09
Source
Stock Titan
Simply Wall Street Direct company coverage

Following FDA Clearance, Is Beam Therapeutics (BEAM) Already Priced In?

Beam Therapeutics (BEAM) has seen its investigational new drug application for BEAM-304 cleared by the FDA, allowing a Phase 1/2 trial to proceed for phenylketonuria patients. Despite a strong share price performance over the past year, the article explores whether the stock, cur

Tone
Positive 64/100
Event
Regulatory and legal
Published
02 Jul 2026 10:09
Source
Simply Wall Street
Finviz Direct company coverage

BEAM - Beam Therapeutics Inc Latest SEC Filings

This article provides the latest SEC filings and comprehensive financial overview for Beam Therapeutics Inc. (BEAM). It includes detailed financial metrics such as market capitalization, income, sales, EPS, P/E ratios, employee count, and stock performance data, offering a snapsh

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 10:09
Source
Finviz
Stock Titan Direct company coverage

Beam Therapeutics (BEAM) CEO exercises options and sells 50K shares under plan

Beam Therapeutics (BEAM) CEO John M. Evans exercised options for 50,000 shares and subsequently sold the same number of shares through open-market transactions at weighted average prices in the mid-$30s. These transactions were carried out under a pre-arranged Rule 10b5-1 trading

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 19:39
Source
Stock Titan
Stock Titan Direct company coverage

BEAM (NASDAQ: BEAM) insider files to sell 25,000 shares via option exercise

An insider at Beam Therapeutics Inc. (NASDAQ: BEAM) filed a Form 144 to sell 25,000 common shares through a stock option exercise on June 29, 2026. This regulatory filing indicates an intent to sell, and similar prior transactions by John M. Evans were detailed, including sales i

Tone
Neutral 50/100
Event
Regulatory and legal
Published
30 Jun 2026 08:42
Source
Stock Titan